Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions caused by skin barrier dysfunction and T helper (Th)2 cell-mediated immunity.
| INTRODUC TI ON
Interleukin (IL)-31, a cytokine cloned by Dillon et al in 2004 , is primarily secreted by activated T cells, especially T helper (Th)2 cells. [1] Atopic dermatitis (AD) is characterized by pruritus and recurrent eczematous lesions that are accompanied by Th2 cell infiltration. [2] [3] [4] [5] The severity of AD (SCORAD: SCORing Atopic Dermatitis) and serum IL-31 concentration show a positive correlation. [3, 6] Furthermore, several studies have reported an association of IL-31
with inflammatory skin diseases with severe pruritus including AD, prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid and cutaneous T-cell lymphoma. [7] [8] [9] [10] [11] Recently, it was reported that the IL-31 receptor is expressed in the peripheral nerves of mice and humans, [12] suggesting that IL-31
secreted by Th2 cells may act directly on peripheral nerves in causing the pruritus associated with AD. Furthermore, clinical studies have demonstrated that blockade of IL-31 signals by a specific antibody effectively mitigates AD-associated pruritus. [13, 14] This review summarizes recent reports on IL-31 and its receptor in the context of AD.
| THE SOURCE OF IL-31
IL-31 belongs to the IL-6 family of cytokines, but unlike other members of this cytokine family, IL-31 signalling does not require the gp130 receptor subunit. [15] IL-31 is primarily produced by Th2 cells. Previous reports have suggested that IL-31 is upregulated in pruritic AD and prurigo nodularis but not pruritic psoriasis. [7] IL-31 is also regulated by allergen exposure, and IL-31 expression by peripheral blood mononuclear cells (PBMCs) upon stimulation with Staphylococcal superantigen. [7] UVB irradiation and reactive oxygen species induce IL-31 expression in human T cells, monocytes and monocyte-derived dendritic cells. [16] Although these findings were obtained using in vitro experiments, they suggest that
Staphylococcus aureus colonization and production of superantigen may stimulate the IL-31 production.
Although main source of IL-31 is Th2 cells, recent studies have suggested that granulocytes are an additional source of IL-31.
[ [17] [18] [19] [20] Human β-defensins and cathelicidin stimulate human mast cells to produce and secrete IL-31. [18] In addition, serum levels of IL-31 are elevated in patients with myeloproliferative disorders (MPDs), which [21] Human basophils serve as a source of IL-31 in the skin of chronic spontaneous urticaria patients. [17] 
| THE RECEP TOR OF IL-31
The receptor for IL-31 consists of a heterodimer of IL-31 receptor α-chain (IL-31RA) and oncostatin M receptor β-chain (OSMR β).
Intracellular signalling involving binding of the IL-31 receptor by IL-31 is mediated by the Janus kinase (JAK)-signal transducer and activator of transcription (STAT), phosphatidylinositol-3 kinase (PI3K)/ AKT (also known as protein kinase B or PKB) and mitogen-activated protein kinase (MAPK) pathways (Figure 1 ). [15, 22] Phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) alone is insufficient to activate JAK1/JAK2 and STAT3. [23, 24] Furthermore, it has been reported that missense mutations in the OSMR β gene were identified in the patients of familial primary localized cutaneous amyloidosis (FPLCA), hereditary skin disease associated with severe pruritus and deposition of amyloid material in the dermis. [25] [26] [27] OSMRβ is a component of IL-31R and OSM type II receptor. FPLCA keratinocytes were stimulated with OSM and IL-31, the expression levels of phosphorylated STATs, ERK1/2 and AKT were reduced. As JAK/STAT, ERK1/2 and PI3K/AKT signalling pathways are known to have anti-apoptotic effect in several tumor cell lines, apoptosis and accumulation of degenerate keratinous material deposition in the dermis may occur in the OSMRβ mutated FPLCA patients. [25] These findings suggested that OSM and IL-31 signalling had been implicated in keratinocyte cell proliferation, differentiation, apoptosis and inflammation.
| TARG E T CELL S AND EFFEC TS OF IL-31
IL-31RA is expressed by immune cells such as activated macrophages, dendritic cells, eosinophils and basophils, as well as by epidermal keratinocytes and cutaneous peripheral nerves ( Figure 2 ). [12, 17, 19, 28] 
| Immune cells
The levels of IL-31RA expressed on human monocytes and macrophages are significantly elevated by Staphylococcal exotoxins. [29] Human dendritic cells significantly upregulate IL-31RA expression upon stimulation with interferon (IFN)-γ, and IL-31-stimulated dendritic cells release several pro-inflammatory cytokines such as tumor necrosis factor TNF)-α, IL-6, CXCL8, CCL2 CCL5 and CCL22. [30] IL-31RA expression by human mast cells is also upregulated by FcεRI aggregation. [31] Human basophils also express IL-31 receptors.
IL-31 was shown to induce the secretion of IL-4 and IL-13 by basophils in vitro and to stimulate basophil chemotaxis. [17] IL-31-stimulated human eosinophils produced pro-inflammatory cytokines (IL-6 and IL-1α) and chemokines (eg CXCL1, CCL2 and CCL5). Moreover, these phenomena were significantly upregulated in eosinophils cocultured with fibroblasts or keratinocytes in conjunction with IL-31 stimulation. [19, 20] 
| Epidermal keratinocytes
Human epidermal keratinocytes abundantly express IL-31RA and
OSMRβ. Epidermal keratinocytes of AD patients express high levels of IL-31RA compared with those of healthy subjects. IL-31 (NHEKs). [1] In addition, IL-31 affects keratinocyte differentiation. IL-31 was shown to reduce the expression of epidermal keratinocyte differentiation-associated molecules such as filaggrin, cytokeratin 10 and involucrin in a 3D skin model using both NHEKs and HaCaT cells conditionally expressing the IL-31RA subunit. In these models, IL20
and IL24 mRNA expressions were induced upon IL-31 application within one hour. These findings suggest that IL-31-dependent regulation of IL-20 and IL-24 is involved in the keratinocyte differentiation in the downstream effect of IL-31. [32] Skin barrier dysfunction in AD was highlighted the link between the incidence of AD and loss-offunction mutations in the filaggrin gene. [4] As the filaggrin expression is downregulated by IL-31, IL-31 may be involved in the pathogenesis of AD.
Yet IL-31 also upregulates the expression of antimicrobial peptides (AMPs), including S100A7, S100A8, S1000A9, β-defensin 2 and β-defensin 3, dependent on IL-1α activation. [33] IL-31 promotes the release of these AMPs and the expression of S100A7 and S100A9
in a 3D skin model using HaCaT cells conditionally expressing the IL-31RA subunit. A dose of 10-100 ng/mL IL-31 was enough to prevent the expression of keratinocyte differentiation molecules including filaggrin. Lower doses of IL-31 (around 1 ng/mL) did not affect the expression of filaggrin; however, it promoted the expression of AMPs.
These data indicate that IL-31 has bifunctional effects on epidermal barrier (Table 1 ).
| Cutaneous peripheral nerves and neuronal spreading
IL-31 has been implicated causing the severe pruritus associated with AD. Both IL-31 transgenic (Tg) mice and mice treated with IL-31 via an iso-osmotic pump exhibited scratching behaviour and AD-like skin lesions. [34] IL-31RA and OSMRβ are co-expressed by sensory neurons. Large-diameter peripheral nerves, such as motor nerves, do not express IL-31 receptor, whereas approximately half of the small peripheral nerves (including C-fibres, which are important for itch transmission) express IL-31RA. [12] In addition, a recent study demonstrated that the transgenic IL31 overexpression and subcutaneously delivered IL-31 induced an increase in the cutaneous nerve fibre density in lesional skin. [34] Culture of whole dorsal root ganglia (DRG) in vitro with IL-31 for 3 days was shown to result in increased neuronal growth and nerve elongation in murine smalldiameter DRG neurons. [34] These phenomena were independent of transient receptor potential cation channel subfamily V member 1 (Trpv1) but dependent upon STAT3. These findings suggested that IL-31 can promote sensitivity to minimal stimuli including sustained pruritus in human AD. Thus, the IL-31 nerve axis may play a role in the skin hypersensitivity that is characteristic of AD. [34] TA B L E 
| NE W TARG E TS FOR AD -A SSO CIATED PRURITUS
Nemolizumab, an anti-IL-31 receptor humanized monoclonal antibody, was developed as a novel therapeutic strategy for targeting pruritus associated with AD. Nemolizumab targets the receptor IL-31RA, inhibiting binding between IL-31 and IL-31RA.
In a randomized, double-blind, placebo-controlled phase I/IIb clinical trial, nemolizumab was administered in a single subcutaneous dose to healthy donors and AD patients, which is a first trial for humans. [14] Furthermore, a randomized, double-blind, placebo-controlled, phase II clinical trial of nemolizumab was conducted in patients with moderate-to-severe AD to evaluate the optimal dose, safety and efficacy. The study showed that anti-IL-31 antibody is effective for improving the clinical symptoms and pruritus associated with AD. [13] Approximately 50 moderate-to-severe AD patients were randomly defined to assess clinical signs of AD. [35] This is helpful for standardization of measurement instruments to evaluate clinical signs of AD. In addition, during this trial, patients were permitted to use emollients.
Patients who had no improvement on the pruritus VAS and clinical manifestation were permitted to use a topical glucocorticoid as rescue therapy at or after week 4. We had to consider the potential confounders as treatment of topical glucocorticoid and primary end point.
However, IL-31 involved pruritus directly and might affect the cutaneous nerve elongation. Itch-scratch cycle-associated lichenoid skin condition might be a good therapeutic target by blocking IL-31. In addition, it has recently been reported that SNPs within IL-31 gene were significantly associated with intrinsic AD. Although the functions of these SNPs have not been described, the stimulation of peripheral blood mononuclear cells (PBMCs) with anti-CD3 and anti-CD28 induced IL-31 mRNA expression, and this expression was higher in individuals who have SNPs within IL-31 gene compared with non-carriers. [36] These findings suggested that genetic factors may influence the intrinsic AD, and that nemolizumab may be a good therapeutic strategy to treat intrinsic AD.
Moreover, prurigo nodularis is an eruption of lichenified or excoriated nodules caused by intractable pruritus. [37] The IL-31 mRNA expression of prurigo nodularis was upregulated compared with that of healthy skin. In addition, the transcript of IL-31 of prurigo nodularis was 4.5-fold upregulated compared with that of lesional AD.
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